April 23, 2009 - During the Jeffrey Modell Foundation (JMF) Annual Spring Ahead Banquet, Biotest and Prof. Dr. Gregor Schulz were honored by the foundation as “Dream Makers” who have helped the JMF realize the dream of providing much needed therapies and research for individuals with Primary Immune Deficiency. Prof. Dr. Schulz, Chief Executive Officer of Biotest AG, was honored and awarded for the work of Biotest in assisting JMF dreams come true. Leading Immunologists, Researchers and pharmaceutical companies from around the world were also recognized. Vicki Modell, Co-Founder of JMF said, "It was certainly the very best event that the Jeffrey Modell Foundation has ever had, and we were so pleased to honor Prof. Dr. Schulz with our “Dream Makers” Award that night."

Biotest AG is a leading worldwide provider of Immune Globulin therapies.

Biotest Pharmaceuticals continues with its development of an Intravenous Immune Globulin in Boca Raton for the US market and supports JMF's dedication to early and precise diagnosis, meaningful treatments, and ultimately cures of the ever increasing known Primary Immunodeficiency Diseases.

About Biotest Pharmaceuticals Corporation

Biotest Pharmaceuticals researches and manufactures biotherapeutic products with a specialization in immunology and liver transplant therapy. Biotest Pharmaceuticals was formed in 2007 as part of the acquisition of Nabi Biopharmaceuticals’ Biologics business unit which includes its plasmapheresis centers across the United States by Biotest AG. The company employs more than 600 people in the US. Biotest Pharmaceuticals is a subsidiary of Biotest AG, a German-based global provider of plasma proteins therapies and diagnostics that employs approximately 1,950 people worldwide. To learn more about Biotest Pharmaceuticals and how we help make a difference in the lives of patients and the healthcare community, please visit us at www.biotestpharma.com.

About Biotest AG

Biotest AG, Dreieich, Germany, is a company that researches and manufactures pharmaceutical, biotherapeutic and diagnostic products and has specialised in the areas of application of immunology and haematology. In its Plasma Protein segment, Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In the Biotherapeutic segment, Biotest researches into the clinical development of monoclonal antibodies, including in the indications of rheumatoid arthritis and cancer of plasma cells. The products of the Microbiological Monitoring segment are primarily used in hygiene monitoring, while those of Medical Diagnostics are used, for example, in blood transfusions and transplants. Biotest has more than 1,950 employees worldwide. The shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

Contacts:

Biotest Pharmaceuticals Corporation
5800 Park of Commerce Blvd. NW
Boca Raton, FL 33487 USA
Telephone: (800) 327-7106
Customer Service: (800) 458-4244
www.biotestpharma.com
media@biotestpharma.com